Physician profile
John Manis
NPI 1720072424
$66,138.39
in general payments reported to CMS, 2019-2025
6 companies · $41K in 2025
The $41K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11K · 2022: $2,275 · 2023: $106 · 2024: $12K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $37K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Travel and Lodging: $2,195 · Food and Beverage: $997 · Education: $68.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $37,161.32 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,367.50 |
| Travel and Lodging | $2,195.34 |
| Food and Beverage | $997.02 |
| Education | $68.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $40,304.70 | 2024-2025 | |
| Sanofi US Services INC. | $11,074.00 | 2020 | |
| Gamida Cell INC. | $10,500.00 | 2025 | Aphexda |
| Terumo Bct, INC. | $3,784.53 | 2022-2025 | Trima Accel, Spectra Optia, Spectra Optia |
| Genetix Biotherapeutics INC | $419.34 | 2025 | Lyfgenia |
| Werfen USA LLC | $55.82 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Manis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.